tacrine and fluvoxamine

tacrine has been researched along with fluvoxamine in 15 studies

Research

Studies (15)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (26.67)	18.2507
2000's	5 (33.33)	29.6817
2010's	5 (33.33)	24.3611
2020's	1 (6.67)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA	1
Dansette, PM; Fontana, E; Poli, SM	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Glen, RC; Lowe, R; Mitchell, JB	1
Ekins, S; Williams, AJ; Xu, JJ	1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Beaune, P; Becquemont, L; Le Bot, MA; Riche, C	1
Becquemont, L; Funck-Brentano, C; Jaillon, P; Le Bot, MA; Ragueneau, I; Riche, C	1
Beaune, P; Becquemont, L; Funck-Brentano, C; Jaillon, P; Le Bot, MA; Riche, C	1
Brøsen, K; Hansen, LL; Larsen, JT; Spigset, O	1
Bader, A; Meng, Q; Ru, J; Schmitmeier, S; Shen, C; Zhang, G	1
Cheng, Z; Gong, B; Li, W; Liao, Y; Liu, Y; Peng, Y; Ran, G; Wang, X; Wu, C; Zheng, J	1

Reviews

1 review(s) available for tacrine and fluvoxamine

Article	Year
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Current drug metabolism, 2005, Volume: 6, Issue:5 Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic	2005

Trials

2 trial(s) available for tacrine and fluvoxamine

Article	Year
Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clinical pharmacology and therapeutics, 1997, Volume: 61, Issue:6 Topics: Adult; Area Under Curve; Cholinesterase Inhibitors; Cross-Over Studies; Cytochrome P-450 CYP1A2 Inhibitors; Double-Blind Method; Fluvoxamine; Humans; Male; Reference Values; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Tacrine	1997
Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. European journal of clinical pharmacology, 1999, Volume: 55, Issue:5 Topics: Adult; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 CYP1A2; Drug Interactions; Fluvoxamine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Tacrine	1999

Article

Year

Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans.

Clinical pharmacology and therapeutics, 1997, Volume: 61, Issue:6

Topics: Adult; Area Under Curve; Cholinesterase Inhibitors; Cross-Over Studies; Cytochrome P-450 CYP1A2 Inhibitors; Double-Blind Method; Fluvoxamine; Humans; Male; Reference Values; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Tacrine

1997

Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo.

European journal of clinical pharmacology, 1999, Volume: 55, Issue:5

Topics: Adult; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 CYP1A2; Drug Interactions; Fluvoxamine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Tacrine

1999

Other Studies

12 other study(ies) available for tacrine and fluvoxamine

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations	2002
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
Predicting phospholipidosis using machine learning. Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5 Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24 Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility	2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Influence of fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatotoxicity in vivo. Fundamental & clinical pharmacology, 1996, Volume: 10, Issue:2 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2 Inhibitors; Drug Interactions; Fluvoxamine; Humans; Microsomes, Liver; Tacrine	1996
Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics, 1998, Volume: 8, Issue:2 Topics: Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Drug Interactions; Enzyme Inhibitors; Fluvoxamine; Humans; Hydroxylation; Microsomes, Liver; Nootropic Agents; Recombinant Proteins; Tacrine	1998
Re-evaluation of tacrine hepatotoxicity using gel entrapped hepatocytes. Toxicology letters, 2007, Jan-30, Volume: 168, Issue:2 Topics: Albumins; Animals; Antidepressive Agents, Second-Generation; Cell Survival; Cells, Cultured; Chemical and Drug Induced Liver Injury; Cholinesterase Inhibitors; Cytochrome P-450 CYP1A2; Female; Fluvoxamine; Gels; Glutathione; Glyceraldehyde-3-Phosphate Dehydrogenases; Glycyrrhetinic Acid; Hepatocytes; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Tacrine; Tetrazolium Salts; Thiazoles	2007
Mechanistic Study of Xanthotoxin-Mediated Inactivation of CYP1A2 and Related Drug-Drug Interaction with Tacrine. Chemical research in toxicology, 2023, 03-20, Volume: 36, Issue:3 Topics: Animals; Cytochrome P-450 CYP1A2; Drug Interactions; Fluvoxamine; Methoxsalen; Rats; Tacrine	2023